Silver Book Fact

After 54 weeks of receiving bevacizumab, wet age-realted macular degeneration (AMD) patients were more likely to gain at least 6 letters of contrast sensitivity than patikents recieving standard care–35.4% versus 15.2%.

Patel, J. Praveen, Fred K. Chen, Lyndon Da Cruz, Gary S. Rubin, Adnan Rufail; for the ABC Trial Study Group. Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. February 2011; 52(6): 3089-93. http://www.iovs.org/content/early/2011/02/09/iovs.10-6208.full.pdf

Reference

Title
Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration
Publication
Invest Ophthalmol Vis Sci
Publication Date
February 2011
Authors
Patel, J. Praveen, Fred K. Chen, Lyndon Da Cruz, Gary S. Rubin, Adnan Rufail; for the ABC Trial Study Group
Volume & Issue
Volume 52, Issue 6
Pages
3089-93
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Intensive glucose control (3 or more daily insulin injections or continuous subcutaneous insulin infusion) reduced the mean risk of retinopathy by 76% in type 1 diabetes patients who had not…  
  • Eye Exams: Trends, 1996-2006 (in relation to screening for diabetic retinopathy)  
  • Cytokines in urine are associated with age-related macular degeneration (AMD) and could be developed as a biomarker and provide a practical tool for early detection  
  • Prescription eye drops could delay or prevent half of glaucoma cases in African Americans.  
  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.